Orion Portfolio Solutions LLC Grows Position in IQVIA Holdings Inc. (NYSE:IQV)

Orion Portfolio Solutions LLC increased its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 2.3% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 16,319 shares of the medical research company’s stock after buying an additional 364 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in IQVIA were worth $3,867,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the stock. First Foundation Advisors lifted its position in IQVIA by 3.8% during the 2nd quarter. First Foundation Advisors now owns 1,161 shares of the medical research company’s stock worth $245,000 after acquiring an additional 43 shares during the period. Invera Wealth Advisors LLC lifted its position in IQVIA by 0.3% during the 2nd quarter. Invera Wealth Advisors LLC now owns 14,506 shares of the medical research company’s stock worth $3,183,000 after acquiring an additional 46 shares during the period. Private Trust Co. NA lifted its position in IQVIA by 10.7% during the 3rd quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock worth $115,000 after acquiring an additional 47 shares during the period. Oregon Public Employees Retirement Fund lifted its position in IQVIA by 0.3% during the 2nd quarter. Oregon Public Employees Retirement Fund now owns 15,668 shares of the medical research company’s stock worth $3,313,000 after acquiring an additional 48 shares during the period. Finally, Continuum Advisory LLC lifted its position in IQVIA by 3.3% during the 2nd quarter. Continuum Advisory LLC now owns 1,538 shares of the medical research company’s stock worth $325,000 after acquiring an additional 49 shares during the period. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Stock Performance

Shares of IQV stock opened at $206.57 on Tuesday. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The stock has a fifty day moving average price of $214.57 and a 200 day moving average price of $224.96. The stock has a market cap of $37.49 billion, a PE ratio of 27.11, a P/E/G ratio of 2.08 and a beta of 1.49. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73.

Analysts Set New Price Targets

A number of research firms have weighed in on IQV. Redburn Atlantic began coverage on IQVIA in a research report on Monday, October 14th. They set a “buy” rating and a $276.00 price objective for the company. The Goldman Sachs Group reduced their price target on IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a report on Friday, November 1st. Evercore ISI reduced their price target on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. StockNews.com cut IQVIA from a “buy” rating to a “hold” rating in a report on Thursday, November 28th. Finally, Leerink Partners reissued an “outperform” rating and issued a $248.00 price target (down from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Five equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $256.50.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.